An email has been sent to your address with instructions for changing your password.
There is no user registered with this email.
Sign Up
To create a free account, please fill out the form below.
Thank you for signing up!
A confirmation email has been sent to your email address. Please check your email and follow the instructions in the message to complete the registration process. If you do not receive the email, please check your spam folder or contact us for assistance.
Welcome to our platform!
Oops!
Something went wrong while trying to create your new account. Please try again and if the problem persist, Email Us to receive support.
Avacta Appoints Dr Christina Coughlin as Non-Executive Director
Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Very Positive)
Tags
management
Rhea-AI Summary
Avacta Group has appointed Dr. Christina Coughlin as a Non-executive Director, effective immediately. Dr. Coughlin is the CEO of CytoImmune Therapeutics and has extensive experience in biotechnology and pharmaceuticals, previously serving in leadership roles at Rubius Therapeutics and Immunocore. Her appointment is expected to enhance Avacta’s strategic direction in developing innovative cancer therapies using its Affimer® and pre|CISION™ platforms. The CEO and Chairman expressed confidence in her ability to contribute to the company's growth and clinical programs.
Positive
Appointment of Dr. Christina Coughlin expected to strengthen leadership.
Dr. Coughlin brings significant experience in oncology and drug development.
Her expertise may enhance Avacta's strategy in cancer therapy development.
Negative
None.
CAMBRIDGE & WETHERBY, England--(BUSINESS WIRE)--
Avacta Group plc (AIM: AVCT), a clinical stage biopharmaceutical company developing innovative cancer therapies and powerful diagnostics based on its proprietary Affimer® and pre|CISION™ platforms announces the appointment of Christina Coughlin, M.D., Ph.D., as Non-executive Director to the Board with immediate effect.
Dr. Coughlin is the Chief Executive Officer of CytoImmune Therapeutics, Inc., a clinical stage biotechnology company, focused on the development and commercialisation of novel cancer immunotherapy products utilising engineered allogeneic natural killer cells to stimulate the patient’s immune system and eliminate cancer cells. Dr. Coughlin has a broad background in biotechnology and global pharmaceuticals, with comprehensive drug development experience spanning programmes in pre-Investigational New Drug (IND) studies through late-stage trials and regulatory approval filings, and a track record of building drug development teams in global companies.
Dr. Coughlin previously served as Chief Medical Officer to Rubius Therapeutics, Inc., where she led the clinical development, translational medicine and regulatory efforts for the company’s programmes emerging from its allogeneic red cell therapy platform. Prior to Rubius, Dr. Coughlin was with Tmunity Therapeutics, Inc., where she served as Chief Medical Officer and was responsible for the development of autologous CAR-T and TCR-T cellular therapies.
Dr. Coughlin has held other leadership roles in the pharmaceutical and biotechnology fields in her career, including Chief Medical Officer at Immunocore, heading the development of the soluble TCR platform, and Oncology Asset Team Leader at Pfizer. Dr. Coughlin received her M.D. and Ph.D. from the University of Pennsylvania and completed fellowships in Haematology and Oncology at the Children’s Hospital of Philadelphia and in the Translational Research Group under the direction of Carl June, M.D., at the University of Pennsylvania.
Dr. Christina Coughlin, commented:“I find the Affimer® and pre|CISION™ platforms to be highly innovative in the oncology field. I look forward to joining the Board and working with my new colleagues and the Avacta management team to develop novel therapies that will improve the lives of patients suffering from cancer.”
Dr. Alastair Smith, Chief Executive Officer of Avacta Group, commented:“I am very pleased, indeed, to welcome Christina to Avacta and the Board. Christina is a vastly experienced biotech executive and oncologist, and Avacta will benefit greatly from her knowledge and expertise in shaping the future strategy for the therapeutic business.”
Dr. Eliot Forster, Chairman of Avacta Group, commented: “I am delighted that Christina will be joining the Board of Avacta. Christina will bring a wealth of clinical and drug development experience and expertise which will be invaluable as we progress our pipeline of proprietary Affimer® and pre|CISION™ programmes in the clinic. I look forward to working with her again on the Avacta Board.”
Who is Dr. Christina Coughlin and what is her role at Avacta Group?
Dr. Christina Coughlin is the newly appointed Non-executive Director at Avacta Group, effective immediately. She is also the CEO of CytoImmune Therapeutics and has a strong background in biotechnology and pharmaceuticals.
What experience does Dr. Coughlin bring to Avacta Group?
Dr. Coughlin has extensive experience in drug development and has held leadership positions at companies like Rubius Therapeutics and Immunocore, focusing on oncology.
What impact might Dr. Coughlin's appointment have on Avacta Group?
Her appointment is expected to provide valuable insights for Avacta's strategic direction and enhance the development of its proprietary cancer therapies.
Immunocore Holdings plc American Depositary Shares
